Search

EDINBURGH, Scotland, Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ('TC BioPharm' or the 'Company') (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for [...]

SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ('MediLink'), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc. [...]

Summary T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize [...]

IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohort SAN JOSE, Calif., July 23, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4216653-1&h=1082777163&u=https%3A%2F%2Fwww.anixa.com%2F&a=Anixa+Biosciences%2C+Inc.('Anixa' or [...]

Team famous for HIV breakthroughs demonstrates both persistent COVID virus and widespread immune activation in long COVID; provides clear targets for treatment Key points: SARS-CoV-2 double-stranded RNA indicative of viral [...]

SINGAPORE, June 30, 2024 /PRNewswire/-- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and [...]

GC Cell and PT Bifarma Adiluhung announced a strategic partnership to facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell therapy for HCC into the Indonesian market. YONGIN, South [...]

New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody [...]

Hospital will be able to provide life-saving bone marrow transplants andCAR T-cell therapy cancer treatments to Central Valley Kids MADERA, Calif., May 3, 2024 /PRNewswire/ -- Valley Children's Healthcare this [...]

Leukemia, lymphoma, and HIV indications initial focus of targeted immune enhancement treatment using Caring Cross' proprietary lentiviral vectors RIO DE JANEIRO and GAITHERSBURG, Md., March 26, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4071701-1&h=3362727797&u=https%3A%2F%2Fportal.fiocruz.br%2Fen&a=Funda%C3%A7%C3%A3o+Oswaldo+Cruz(Fiocruz), [...]

SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 29, 2024 /PRNewswire/ -- On February 26, 2024, the impactful international academic journal,EMBO Molecular Medicine, published the clinical data of the [...]

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 [...]

FDA IND Clearance for CHM 2101, a novel 3[sup.rd] generation CDH17 CAR T cell therapy Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic Phase [...]

Coeptis now has exclusive rights to SNAP-CAR NK and SNAP-CAR T-Cell technology platforms WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ('Coeptis' or 'the Company'), [...]

VIENNA, June 21, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3892252-1&h=736829792&u=http%3A%2F%2Fwww.viriontx.com%2F&a=Virion+Therapeutics%2C+LLC%2C a clinical stage company developing T cell-based immunotherapies for cancer and chronic infectious diseases, today, presented data entitled'Intrahepatic CD8[sup.+] T cells correlate with [...]

Phase 1 open-label clinical trial in LN in U.S. is actively recruiting patients at multiple sites KYV-101 is a novel, fully human anti-CD19 chimeric antigen receptor T-cell therapy designed to [...]

AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., May 31, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3880258-1&h=3321268874&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3865969-1%26h%3D823620646%26u%3Dhttps%253A%252F%252Ftriumvira.com%252F%26a%3DTriumvira%2BImmunologics&a=Triumvira+Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt [...]

SNAP-CAR represents a major advance potentially expanding the targeting capabilities of chimeric antigen receptor (CAR) T cells for various cancers and other indications WEXFORD, Pa., May 10, 2023 /PRNewswire/ -- [...]

Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of [...]

ROCKVILLE, Md., May 2, 2023 /PRNewswire/ -- Cellular Biomedicine Group Inc. (CBMG or the Company), a clinical-stage biopharmaceutical company focused on discovery and development of innovative cellular therapies for cancer [...]

OEGSTGEEST, The Netherlands, April 27, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it [...]

SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, [...]

MetroHealth is the second public hospital and first safety-net hospital in the U.S. to offer in-house viral vector production CLEVELAND, March 30, 2023 /PRNewswire/ -- MetroHealth today announced the completion [...]

Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. [...]

SÖDERTÈäLJE, Sweden, Dec. 21, 2022 /PRNewswire/ -- Anocca, a fully integrated cell therapy biotechnology company, today announced that it has secured EUR 25 million Venture Debt financing from the European [...]

SOLNA, Sweden, Dec. 20, 2022 /PRNewswire/ --As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology platforms for its therapeutic Herpes simplex virus type [...]

The inaugural award will help develop clinic-ready CAR T therapies LOS ANGELES, Dec. 7, 2022 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in [...]

DuraCAR Drug Addresses Major Need in Solid Tumor Therapies SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)has recently discussed the use [...]

--Overall Response Rate 30.4 Percent in 23 Evaluable Patients Including Two Complete Responses and a Third Cancer-Free Patient-- --Vaccination-Related Adverse Events Limited to Grades 1 and 2 Only-- --100 Percent [...]

SAN JOSE, Calif., Oct. 31, 2022 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3692859-1&h=3746598187&u=http%3A%2F%2Fwww.anixa.com%2F&a=Anixa+Biosciences%2C+Inc.(NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of [...]

Understanding CAR-T Mechanism of Action SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year [...]

SAB selected to advance new therapeutic trials and strategic partnerships EDINBURGH, Scotland, Oct. 26, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ('TC BioPharm' or the 'Company') (NASDAQ: TCBP) (NASDAQ: TCBPW), [...]

- Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis - Kyverna's [...]

Agreement grants Eterna rights to license up to four next-generation iPS cell derived NK and T cell cancer therapies License terms include an upfront license fee, development and commercialization milestone [...]

Trial is the first of its kind to evaluate a combined COVID-19 and influenza vaccine Dose insights from Phase 1/2 trial will inform Phase 2 confirmation trial to begin in [...]

Anti-HIV DuoCAR-T cell therapy offers potential to eliminate HIV-infected cells and suppresses HIV infection long-term in the body Groundbreaking clinical trial being conducted in collaboration with University of California, San [...]

SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, [...]

The LLS National Patient Registry Reports Data on T-cell Production from COVID-19 Vaccines LLS thanks the family of Michael Garil, and his parents Bernie and Ethel Garil, for their support [...]

The LLS National Patient Registry Reports Data on T-cell Production from COVID-19 Vaccines RYE BROOK, N.Y., Sept. 8, 2022 /PRNewswire/ -- A new study from https://c212.net/c/link/?t=0&l=en&o=3642895-1&h=1488531544&u=https%3A%2F%2Fwww.lls.org%2F&a=The+Leukemia+%26+Lymphoma+Society(LLS), published in Blood Cancer [...]

First orphan drug designation granted for Nana-val by the European Commission; fifth globally SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3640401-1&h=3339721851&u=http%3A%2F%2Fwww.viracta.com%2F&a=Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting [...]

SEOUL, South Korea, July 12, 2022 /PRNewswire/ -- On the July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing next-generation chimeric [...]

Gladstone scientists uncover novel aspects of HIV infection by monitoring sugars at the surface of individual immune cells SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- HIV researchers have long been [...]

-- ARC-SparX is a novel CAR-T cell therapy treatment designed to allow for controllability and adaptability to potentially reduce toxicities associated with serious dose-limiting adverse events and overcome tumor heterogeneity [...]

Research Revealed the Importance of Testing for Strength of Adhesion to Uncover 'Avidity Escape' in Solid Tumors and Reduce Failure Rates of CAR T Cell Therapies AMSTERDAM, May 2, 2022 [...]

Research Demonstrates Further Evidence of Importance of Cell Avidity to Improving Cell Therapy Design to Target Cancer Cells AMSTERDAM, March 17, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools [...]

DALLAS, March 14, 2022 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. [...]

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 21, 2022 /PRNewswire/ -- recently -- Adlai Nortye Ltd. ('Adlai Nortye'), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, [...]

SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX)('BioVaxys' or 'Company') announced [...]

Scientists from St. Jude Children's Research Hospital and Washington University in St. Louis have analyzed the T cells that respond to mRNA vaccination and paint a hopeful picture for lasting [...]

INO-4800 has maintained broad T cell responses against previously known variants of concern PLYMOUTH MEETING, Pa., Nov. 30, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to [...]